A61K 40/10
Cellular immunotherapy: characterised by the cell type used
Official title: characterised by the cell type used
A61K40/10 (Cellular immunotherapy: characterised by the cell type used) appears on 6,267 US grants and 14,352 published applications in this corpus.
Search patents in A61K- Granted patents
- 6,267
- Published applications
- 14,352
- Assignees
- 3,188
- Inventors
- 17,442
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 1 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 2 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 1 | 0 |
| 1989 | 5 | 0 |
| 1990 | 3 | 0 |
| 1991 | 2 | 0 |
| 1992 | 6 | 0 |
| 1993 | 6 | 0 |
| 1994 | 9 | 0 |
| 1995 | 7 | 0 |
| 1996 | 6 | 0 |
| 1997 | 22 | 0 |
| 1998 | 39 | 0 |
| 1999 | 28 | 0 |
| 2000 | 36 | 0 |
| 2001 | 39 | 24 |
| 2002 | 62 | 169 |
| 2003 | 51 | 199 |
| 2004 | 47 | 196 |
| 2005 | 33 | 143 |
| 2006 | 68 | 169 |
| 2007 | 33 | 114 |
| 2008 | 65 | 173 |
| 2009 | 58 | 172 |
| 2010 | 106 | 227 |
| 2011 | 104 | 242 |
| 2012 | 100 | 187 |
| 2013 | 128 | 222 |
| 2014 | 145 | 286 |
| 2015 | 166 | 277 |
| 2016 | 186 | 350 |
| 2017 | 181 | 501 |
| 2018 | 271 | 653 |
| 2019 | 342 | 923 |
| 2020 | 496 | 1134 |
| 2021 | 510 | 1331 |
| 2022 | 536 | 1500 |
| 2023 | 532 | 1400 |
| 2024 | 628 | 1528 |
| 2025 | 711 | 1252 |
| 2026 | 490 | 980 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Inverse agonists of rar related orphan receptors (rors)8 Oct 2026US 2026/0306484 A111949098 CANADA INC. (NUREDCO) c/o Jean I. TCHERVENKOV
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Novel phosphoantigen prodrug compound and use thereof8 Oct 2026US 2026/0306541 A1
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
Most cited
By later US patents
- Gene therapy759US 5,399,346 AThe United States of America as represented by the Department of Health and Human Services · 1995
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells452US 6,534,055 B1Genetics Institute, Inc. · 2003
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005